What Happened?
Cambridge, MA-based Kronos-Bio Appointed Norbert Bischofberger as President and Chief Executive Officer
About the Company
Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.
About the Person
Norbert Bischofberger is President and Chief Executive Officer at Kronos Bio. Previously, Norbert held various senior HR leadership roles in the industry.
Info Source
News
Short Profile